Study of TPX-0046, A RET/SRC Inhibitor in Adult Subjects With Advanced Solid Tumors Harboring RET Fusions or Mutations
Public ClinicalTrials.gov record NCT04161391. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 1/2 Study of TPX-0046, A Novel Oral RET/SRC Inhibitor in Adult Subjects With Advanced/Metastatic Solid Tumors Harboring Oncogenic RET Fusions or Mutations
Study identification
- NCT ID
- NCT04161391
- Recruitment status
- Terminated
- Study type
- Interventional
- Phase
- Phase 1, Phase 2
- Lead sponsor
- Turning Point Therapeutics, Inc.
- Industry
- Enrollment
- 41 participants
Conditions and interventions
Conditions
Interventions
- TPX-0046 Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Dec 5, 2019
- Primary completion
- May 21, 2023
- Completion
- May 21, 2023
- Last update posted
- Jun 12, 2024
2019 – 2023
United States locations
- U.S. sites
- 20
- U.S. states
- 14
- U.S. cities
- 18
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Local Institution - 2129 | La Jolla | California | 92093 | — |
| Local Institution - 2128 | Orange | California | 92868 | — |
| Local Institution - 2122 | Aurora | Colorado | 80045 | — |
| SCRI - HealthOne Denver | Denver | Colorado | 80218 | — |
| Local Institution - 2126 | Washington D.C. | District of Columbia | 20007 | — |
| Mayo Clinic - Jacksonville | Jacksonville | Florida | 32224 | — |
| Local Institution - 2130 | Tampa | Florida | 33612-9416 | — |
| Local Institution - 2127 | Atlanta | Georgia | 30322 | — |
| University of Chicago Medicine | Chicago | Illinois | 60637 | — |
| Massachusetts General Hospital | Boston | Massachusetts | 02114 | — |
| Local Institution - 2124 | Ann Arbor | Michigan | 48109-5000 | — |
| Local Institution - 2131 | Detroit | Michigan | 48201 | — |
| Mayo Clinic - Arizona | Rochester | Minnesota | 55905 | — |
| Mayo Clinic - Rochester | Rochester | Minnesota | 55905 | — |
| Memorial Sloan Kettering Cancer Center | New York | New York | 10021 | — |
| Local Institution - 2137 | Philadelphia | Pennsylvania | 19111 | — |
| Local Institution - 2120 | Houston | Texas | 77030-3721 | — |
| Baylor College of Medicine - Baylor Heart Clinic | Houston | Texas | 77030 | — |
| Local Institution - 2135 | Fairfax | Virginia | 22031 | — |
| Local Institution - 2132 | Seattle | Washington | 98195 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 1 non-U.S. site.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT04161391, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jun 12, 2024 · Synced May 16, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT04161391 live on ClinicalTrials.gov.